Claims for Patent: 5,004,758

Summary for Patent: 5,004,758

Title:	Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
Abstract:	Water soluble camptothecin analogs, pharmaceutical compositions comprising such analogs, and a method of inhibiting the growth of tumor cells sensitive to such analogs in an animal in need thereof.
Inventor(s):	Boehm; Jeffrey C. (King of Prussia, PA), Hecht; Sidney M. (Charlottesville, VA), Holden; Kenneth G. (Malvern, PA), Johnson; Randall K. (Ardmore, PA), Kingsbury; William D. (Wayne, PA)
Assignee:	SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:	07/266,460
Patent Claims:	1. A compound of the formula: ##STR15## wherein: X is hydroxy; hydrogen; --CH.sub.2 NH.sub.2 ; or formyl; R is hydrogen when X is CH.sub.2 NH.sub.2 or formyl; or R is --CHO or --CH.sub.2 R.sup.1 when X is hydrogen or hydroxy; R.sup.1 is --O--R.sup.2 ; --S--R.sup.2 ; --CH.sub.2 NH.sub.2 ; cyano; --N--R.sup.2 (R.sup.3); or --N.sup.+ --R.sup.2 (R.sup.3)(R.sup.4), provided that when R.sup.1 is --N.sup.+ --R.sup.2 (R.sup.3)(R.sup.4 ) the compound is associated with a pharmaceutically acceptable anion; R.sup.2, R.sup.3 and R.sup.4 are the same or different and are selected from H; C.sub.1-6 alkyl; C.sub.2-6 hydroxyalkyl; C.sub.1-6 dialkylamino-C.sub.2-6 alkyl; C.sub.1-6 alkylamino-C.sub.2-6 alkyl; C.sub.2-6 aminoalkyl or a 3-7 member unsubstituted carbocyclic ring; and when R.sup.1 is --N--R.sup.2 (R.sup.3), the R.sup.2 and R.sup.3 groups may be combined together with the nitrogen atom to which they are bonded to form a heterocyclic ring provided that such heterocyclic ring is selected from morpholino, N-methylpiperazinyl, or 4'-piperidinopiperidinyl; or a pharmaceutically acceptable salt, hydrate or solvate thereof. 2. The compound of claim 1 wherein X is hydroxy and R is dimethylaminomethyl, N-morpholinomethyl, N-methylpiperazinylmethyl, (4'-piperidine)N-piperidinylmethyl, (2'-hydroxyethyl)aminomethyl, trimethylammoniummethyl, cyclohexylaminomethyl, N-methylanilinomethyl, ethoxymethyl, cyclopropylaminomethyl, N,N-dimethylaminoethyloxymethyl, N,N-dimethylaminoethylthiomethyl, N,N-dimethylaminoethylaminomethyl, cyanomethyl, aminoethyl or formyl; or wherein R is hydrogen and X is formyl or aminomethyl; or wherein X is hydrogen and R is dimethylaminomethyl or N-morpholinomethyl. 3. The compound of claim 1 which is the S-isomer. 4. The compound of claim 1 which is the racemic mixture. 5. The compound of claim 3 wherein X is hydroxy and R is dimethylaminomethyl. 6. The compound of claim 5 which is the acetate salt. 7. The compound of claim 5 which is the monohydrochloride, dihydrochloride or sodium salt. 8. The compound of claim 3 wherein X is hydroxy and R is trimethylammoniummethyl. 9. The compound of claim 3 wherein X is hydroxy and R is N-methylpiperazinylmethyl. 10. The compound of claim 3 wherein X is hydroxy and R is N-methylanilinomethyl. 11. The compound of claim 3 wherein X is hydroxy and R is cyclohexylaminomethyl. 12. The compound of claim 3 wherein X is hydroxy and R is N,N-dimethylaminoethyloxymethyl. 13. The compound of claim 3 wherein X is hydroxy and R is cyanomethyl. 14. The compound of claim 3 wherein X is hydroxy and R is morpholinomethyl. 15. The compound of claim 3 wherein X is hydroxy and R is aminomethyl. 16. The compound of claim 3 wherein X is hydroxy and R is cyclopropylaminomethyl. 17. A pharmaceutical composition comprising an effective tumor cell growth-inhibiting amount of an active ingredient and an inert pharmaceutically acceptable carrier or diluent, wherein said composition is useful for inhibiting the growth of animal tumor cells sensitive to the active ingredient, and wherein the active ingredient is a compound of the formula: ##STR16## X is hydroxy; hydrogen; --CH.sub.2 NH.sub.2 ; or formyl; R is hydrogen when X is CH.sub.2 NH.sub.2 or formyl; or R is --CHO or --CH.sub.2 R.sup.1 when X is hydrogen or hydroxy; R.sup.1 is --O--R.sup.2 ; --S--R.sup.2 ; --CH.sub.2 NH.sub.2 ; cyano; --N--R.sup.2 (R.sup.3); or --N.sup.+ --R.sup.2 (R.sup.3)(R.sup.4), provided that when R.sup.1 is --N.sup.+ --R.sup.2 (R.sup.3)(R.sup.4) the compound is associated with a pharmaceutically acceptable anion; R.sup.2,R.sup.3 and R.sup.4 are the same or different and are selected from H; C.sub.1-6 alkyl ; C.sub.2-6 hydroxyalkyl; C.sub.1-6 dialkylamino-C.sub.2-6 alkyl; C.sub.1-6 alkylamino-C.sub.2-6 alkyl; C.sub.2-6 aminoalkyl or a 3-7 member unsubstituted carbocyclic ring; and when R.sup.1 is --N--R.sup.2 (R.sup.3), the R.sup.2 and R.sup.3 groups may be combined together with the nitrogen atom to which they are bonded to form a heterocyclic ring provided that such heterocyclic ring is selected from morpholino, N-methylpiperazinyl, or 4'-piperidinopiperidinyl; or a pharmaceutically acceptable salt, hydrate or solvate thereof. 18. The composition of claim 17 wherein X is hydroxy and R is dimethylaminomethyl, N-morpholinomethyl, N-methylpiperazinylmethyl, (4'-piperidine)N-piperidinylmethyl, (2'-hydroxyethyl)aminomethyl, trimethylammoniummethyl, cyclohexylaminomethyl, N-methylanilinomethyl, ethoxymethyl, cyclopropylaminomethyl, N,N-dimethylaminoethyloxymethyl, N,N-dimethylaminoethylthiomethyl, N,N-dimethylaminoethylaminomethyl, cyanomethyl, aminoethyl or formyl; or wherein R is hydrogen and X is formyl or aminomethyl; or wherein X is hydrogen and R is dimethylaminomethyl or N-morpholinomethyl. 19. The composition of claim 17 which is the S-isomer. 20. The composition of claim 17 which is the racemic mixture. 21. The composition of claim 19 wherein X is hydroxy and R is dimethylaminomethyl. 22. The composition of claim 21 which is the acetate salt. 23. The composition of claim 21 which is the monohydrochloride, dihydrochloride or sodium salt. 24. The composition of claim 17 which is in oral dosage form. 25. The composition of claim 17 which is in parenteral dosage form. 26. A method of inhibiting the growth of animal tumor cells sensitive to a compound of the formula: ##STR17## wherein: X is hydroxy; hydrogen; --CH.sub.2 NH.sub.2 ; or formyl; R is hydrogen when X is CH.sub.2 NH.sub.2 or formyl; or R is --CHO or --CH.sub.2 R.sup.1 when X is hydrogen or hydroxy; R.sup.1 is --O--R.sup.2 ; --S--R.sup.2 ; --CH.sub.2 NH.sub.2 ; cyano; --N--R.sup.2 (R.sup.3); or --N.sup.+ --R.sup.2 (R.sup.3)(R.sup.4), provided that when R.sup.1 is --N.sup.+ --R.sup.2 (R.sup.3)(R.sup.4) the compound is associated with a pharmaceutically acceptable anion; R.sup.2,R.sup.3 and R.sup.4 are the same or different and are selected from H; C.sub.1-6 alkyl C.sub.2-6 hydroxyalkyl; C.sub.1-6 dialkylamino-C.sub.2-6 alkyl; C.sub.1-6 alkylamino-C.sub.2-6 alkyl; C.sub.2-6 aminoalkyl or a 3-7 member unsubstituted carbocyclic ring; and when R.sup.1 is --N--R.sup.2 (R.sup.3), the R.sup.2 and R.sup.3 groups may be combined together with the nitrogen atom to which they are bonded to form a heterocyclic ring provided that such heterocyclic ring is selected from morpholino, N-methylpiperazinyl, or 4'-piperidinopiperidinyl; or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein such method comprises administering to an animal afflicted with said tumor cells, an effective, tumor cell growth inhibiting amount of such compound. 27. The method of claim 26 wherein X is hydroxy and R is dimethylaminomethyl, N-morpholinomethyl, N-methylpiperazinylmethyl, (4'-piperidine)N-piperidinylmethyl, (2'-hydroxyethyl)aminomethyl, trimethylammoniummethyl, cyclohexylaminomethyl, N-methylanilinomethyl, ethoxymethyl, cyclopropylaminomethyl, N,N-dimethylamino ethyloxymethyl, N,N-dimethylaminoethylthiomethyl, N,N-dimethylaminoethylaminomethyl, cyanomethyl, aminoethyl or formyl; or wherein R is hydrogen and X is formyl or aminomethyl; or wherein X is hydrogen and R is dimethylaminomethyl or N morpholinomethyl. 28. The method of claim 26 which is the S-isomer. 29. The method of claim 26 which is the racemic mixture. 30. The method of claim 28 wherein X is hydroxy and R is dimethylaminomethyl. 31. The method of claim 30 which is the acetate salt. 32. The method of claim 30 which is the monohydrochloride, dihydrochloride or sodium salt. 33. The method of claim 26 wherein the compound is administered orally. 34. The method of claim 26 wherein the compound is administered parenterally. 35. A compound of the formula ##STR18##